【canker sore from vaping】Boston Scientific to Sell ZelanteDVT Catheter in US, Europe

Boston Scientific Corporation

BSX recently won the U.S. Food and Drug Administration’s (FDA) approval and the CE Mark for its AngioJet ZelanteDVT thrombectomy catheter. Thecanker sore from vaping regulatory clearances make way for the commercialization of the device in the U.S. and European markets, respectively. Notably, the ZelanteDVT catheter specifically aims at curing deep vein thrombosis (DVT) in large-diameter upper and lower limb peripheral veins.

We believe the receipt of these landmark approvals with respect to two key markets will allow this medical technology giant to further bolster its footprint in the global clot management devices market.

DVT, a medical condition involving formation of blood clots in one or more of the deeper veins, often remains underdiagnosed and may lead to serious complications; if not cured at an earlier stage. The most serious complication of DVT occurs when part of the clot breaks off and travels through the bloodstream to the lungs, causing a blockage called pulmonary embolism (PE). In the event of large clots, such complications may actually be fatal for patients.

As per the estimates of the Centers for Disease Control and Prevention (CDC), every year, as many as 900,000 people are potentially affected by DVT/PE in the U.S. alone. Moreover, almost 60,000-100,000 Americans die of these conditions. Such a huge prospective patient pool thus indicates strong scope for Boston Scientific’s ZelanteDVT catheter.

In most of the cases, physicians advise oral as well as injectable anticoagulant drugs to treat DVT/PE. However, as these drugs reduce the ability of blood to clot in a patient, they may cause unusual bleeding. That is why, as a therapeutic alternative, surgeons often perform interventional procedures to remove or break up a clot in DVT patients.

Boston Scientific’s ZelanteDVT is the most powerful thrombectomy catheter in the company’s current market-leading AngioJet portfolio, designed to efficiently remove large venous clots and facilitate rapid restoration of blood flow. Per management, this device potentially reduces the procedural time of removing clots; thereby mitigating complications caused due to delayed treatment.

This apart, the ZelanteDVT catheter also helps control bleeding risks. This reduces the need for future hospitalization, thus saving on costs that are unwarrantedly incurred in the context of this challenging condition.

With the global clot management devices market expected to grow at a CAGR of 5.9% during the period 2014–2019, the aforementioned regulatory approvals in the U.S. and European markets comes in handy for Boston Scientific. Based on these, the company is poised to capture a larger share of this growing market potential, going ahead.

Story continues

Zacks Rank

Currently, the company carries a Zacks Rank #3 (Hold). Some better-ranked medical products stocks are GW Pharmaceuticals plc GWPH, Hill-Rom Holdings, Inc. HRC and ICU Medical, Inc. ICUI. All the three stocks sport a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download

7 Best Stocks for the Next 30 Days.

Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.

Click to get this free report

BOSTON SCIENTIF (BSX): Free Stock Analysis Report

GW PHARMA-ADR (GWPH): Free Stock Analysis Report

HILL-ROM HLDGS (HRC): Free Stock Analysis Report

ICU MEDICAL INC (ICUI): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

View comments

很赞哦!（211）